These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 9951495

  • 41. The effect of latanoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma.
    Oh JY, Park KH.
    Korean J Ophthalmol; 2005 Dec; 19(4):297-301. PubMed ID: 16491821
    [Abstract] [Full Text] [Related]

  • 42. Effects of an unfixed combination of latanoprost and pilocarpine on the intraocular pressure and pupil size of normal dogs.
    Sarchahi AA, Abbasi N, Gholipour MA.
    Vet Ophthalmol; 2012 Mar; 15 Suppl 1():64-70. PubMed ID: 22050700
    [Abstract] [Full Text] [Related]

  • 43. Intraocular pressure (IOP) reduction by latanoprost in Japanese normal tension glaucoma patients over a five-year period stratified by presenting IOP.
    Tsuda M, Ando A, Matsuyama K, Otsuji T, Fukui C, Maenishi N, Kuwahara A, Nishimura T, Jo N, Nambu H, Matsumura M.
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):441-5. PubMed ID: 19857106
    [Abstract] [Full Text] [Related]

  • 44. Latanoprost for uncontrolled glaucoma in a compassionate case protocol.
    Patelska B, Greenfield DS, Liebmann JM, Wand M, Kushnick H, Ritch R.
    Am J Ophthalmol; 1997 Sep; 124(3):279-86. PubMed ID: 9439353
    [Abstract] [Full Text] [Related]

  • 45. Cystoid macular edema associated with the use of latanoprost.
    Gaddie IB, Bennett DW.
    J Am Optom Assoc; 1998 Feb; 69(2):122-8. PubMed ID: 9549261
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents.
    Hoyng PF, Rulo A, Greve E, Watson P, Alm A.
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S93-8. PubMed ID: 9154283
    [Abstract] [Full Text] [Related]

  • 48. A clinical trial with Piloplex--a new long-acting pilocarpine compound: preliminary report.
    Ticho U, Blumenthal M, Zonis S, Gal A, Blank I, Mazor ZW.
    Ann Ophthalmol; 1979 Apr; 11(4):555-61. PubMed ID: 572195
    [Abstract] [Full Text] [Related]

  • 49. [Ocular hypotensive effect of pilocarpine in latanoprost treated eyes; a pilot study].
    Teus Guezala MA, Arranz Márquez E, Morales Bertrand J, Marcos De La Huerga A.
    Arch Soc Esp Oftalmol; 2000 Nov; 75(11):735-740. PubMed ID: 11151262
    [Abstract] [Full Text] [Related]

  • 50. Use of latanoprost to reduce acute intraocular pressure rise following neodymium: Yag laser iridotomy.
    Liu CJ, Cheng CY, Chiang SC, Chiu AW, Chou JC, Hsu WM, Liu JH.
    Acta Ophthalmol Scand; 2002 Jun; 80(3):282-6. PubMed ID: 12059867
    [Abstract] [Full Text] [Related]

  • 51. Effect of topical latanoprost 0.005% on intraocular pressure and pupil diameter in normal and glaucomatous cats.
    McDonald JE, Kiland JA, Kaufman PL, Bentley E, Ellinwood NM, McLellan GJ.
    Vet Ophthalmol; 2016 Jul; 19 Suppl 1(Suppl 1):13-23. PubMed ID: 26183373
    [Abstract] [Full Text] [Related]

  • 52. Additive effect of bunazosin on intraocular pressure when topically added to treatment with latanoprost in patients with glaucoma.
    Tsukamoto H, Jian K, Takamatsu M, Okada K, Mukai S, Tsumamoto Y, Mishima HK.
    Jpn J Ophthalmol; 2003 Jul; 47(5):526-8. PubMed ID: 12967873
    [Abstract] [Full Text] [Related]

  • 53. Potential mechanism for the additivity of pilocarpine and latanoprost.
    Toris CB, Zhan GL, Zhao J, Camras CB, Yablonski ME.
    Am J Ophthalmol; 2001 Jun; 131(6):722-8. PubMed ID: 11384567
    [Abstract] [Full Text] [Related]

  • 54. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma.
    Ang A, Reddy MA, Shepstone L, Broadway DC.
    Br J Ophthalmol; 2004 May; 88(5):630-4. PubMed ID: 15090413
    [Abstract] [Full Text] [Related]

  • 55. Efficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary-body face: a preliminary study.
    Kook MS, Cho HS, Yang SJ, Kim S, Chung J.
    J Ocul Pharmacol Ther; 2005 Feb; 21(1):75-84. PubMed ID: 15718831
    [Abstract] [Full Text] [Related]

  • 56. Clinical experience in the treatment of normal tension glaucoma with latanoprost in Germany.
    Thelen U, Weiler W, Kirchhoff E, Fuchs HB, Stewart WC.
    J Ocul Pharmacol Ther; 2007 Jun; 23(3):311-3. PubMed ID: 17593016
    [Abstract] [Full Text] [Related]

  • 57. The effectiveness and tolerability of fixed-dose combination netarsudil 0.02%/latanoprost 0.005% at a tertiary glaucoma center.
    Wong JC, Shiuey EJ, Razeghinejad R, Shukla AG, Kolomeyer NN, Myers JS, Pro MJ, Lee D.
    Graefes Arch Clin Exp Ophthalmol; 2023 Jan; 261(1):193-200. PubMed ID: 35904596
    [Abstract] [Full Text] [Related]

  • 58. Drug delivery systems for topical ophthalmic medication.
    Halberg GP, Kelly SE, Morrone M.
    Ann Ophthalmol; 1975 Sep; 7(9):1199-1204, 1207-9. PubMed ID: 1163927
    [Abstract] [Full Text] [Related]

  • 59. Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys.
    Ciolino JB, Ross AE, Tulsan R, Watts AC, Wang RF, Zurakowski D, Serle JB, Kohane DS.
    Ophthalmology; 2016 Oct; 123(10):2085-92. PubMed ID: 27586444
    [Abstract] [Full Text] [Related]

  • 60. Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy.
    Hung PT, Hsieh JW, Chen YF, Wei T.
    J Ocul Pharmacol Ther; 2000 Feb; 16(1):43-7. PubMed ID: 10673130
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.